Rice Hall James & Associates LLC Purchases New Holdings in Repligen Co. (NASDAQ:RGEN)

Rice Hall James & Associates LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 15,391 shares of the biotechnology company’s stock, valued at approximately $2,215,000.

Other large investors also recently bought and sold shares of the company. UMB Bank n.a. lifted its position in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 110 shares during the period. First Turn Management LLC purchased a new position in Repligen in the third quarter worth about $13,202,000. Thrivent Financial for Lutherans raised its holdings in Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after buying an additional 36,773 shares during the last quarter. Geneva Capital Management LLC raised its holdings in Repligen by 8.5% in the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock worth $20,638,000 after buying an additional 10,908 shares during the last quarter. Finally, TimesSquare Capital Management LLC raised its holdings in Repligen by 14.6% in the third quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock worth $41,019,000 after buying an additional 35,115 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Trading Down 1.2 %

RGEN stock opened at $145.18 on Wednesday. Repligen Co. has a one year low of $113.50 and a one year high of $207.87. The company’s fifty day moving average price is $155.26 and its 200-day moving average price is $148.82. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RGEN. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. HC Wainwright decreased their target price on shares of Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. TD Cowen started coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. Finally, Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $182.91.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.